H
Harrow, Inc. (HROW)
NGM – Real vaqt narxi. Valyuta: USD
29.03
-9.01 (-23.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NGM – Real vaqt narxi. Valyuta: USD
29.03
-9.01 (-23.69%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Harrow, Inc., ko'z kasalliklari bo'yicha farmatsevtika kompaniyasi, Qo'shma Shtatlarda oftalmik farmatsevtika mahsulotlarini kashf qilish, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. U Branded va ImprimisRx segmentlari orqali faoliyat yuritadi. Kompaniya oftalmologiyaga yo'naltirilgan tayyorlangan dorilar bo'lgan ImprimisRxni taklif etadi. Shuningdek, u xloroprokain gidroxlorid oftalmik jeli bo'lgan IHEEZO; IOPIDINE, VEVYE va ZERVIATE, shuningdek BYQLOVI ni o'z ichiga olgan oftalmik eritmalar; MAXITROL ko'z tomchilari; ILEVRO va NEVANAC, katarakta jarrohligi bilan bog'liq og'riq va yallig'lanish uchun steroid bo'lmagan va yallig'lanishga qarshi ko'z tomchilari; BYOOVIZ, neovaskulyar (nam) yoshga bog'liq makula degeneratsiyasi (AMD), retinal venaning tiqilib qolishi (RVO) dan keyingi makula shishi va miyopik xoroidal neovaskulyarizatsiya (mCNV) bilan og'rigan bemorlarni davolash uchun ko'rsatilgan LUCENTIS biosimilyari; VIGAMOX, bakterial kon'yunktivitni davolash uchun florokinolon antibiotik ko'z tomchilari; OPUVIZ, nam AMD, RVO dan keyingi makula shishi, diabetik makula shishi (DME) va diabetik retinopatiya (DR) bilan og'rigan bemorlarni davolash uchun ko'rsatilgan EYLEA biosimilyari; MAXIDEX va FLAREX, palpebral va bulbar kon'yunktivaning, korneaning va globusning oldingi segmentining steroidga javob beradigan yallig'lanish holatlarini davolash uchun steroid ko'z tomchilari; TRIESENCE, oftalmik kasalliklarni davolash va vitrektomiya paytida vizualizatsiya qilish uchun steroid in'ektsiyasi; va NATACYN, qo'ziqorin blefariti, kon'yunktivit va keratiti davolash uchun steril, antifungal dori. Bundan tashqari, u TOBRADEX ST, tobramitsin va deksametazon oftalmik suspenziyasi; VERKAZIA siklosporin oftalmik emulsiya; NEVANAC, steroid bo'lmagan, yallig'lanishga qarshi ko'z tomchilari; va FRESHKOTE konservantlarsiz (PF) moylash uchun ko'z tomchilari taklif etadi. Kompaniya ilgari Harrow Health, Inc. nomi bilan tanilgan va 2023 yil sentyabr oyida Harrow, Inc. nomini o'zgartirgan. Harrow, Inc. 1998 yilda tashkil etilgan va Neshvill, Tennessi shtatida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Amir W. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance |
| Dr. Prashanth S. Annavajjhala | Chief of Staff |
| Mr. Andrew R. Boll C.F.A., C.M.A. | President, CFO & Corporate Secretary |
| Mr. Brett A. Burrell | Vice President of Legal & Compliance |
| Mr. Mark L. Baum J.D. | CEO, Chairman of the Board & Founder |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-11 | 10-Q | form10-q.htm |
| 2026-04-24 | DEFA14A | formdefa14a.htm |
| 2026-04-24 | DEF 14A | formdef14a.htm |
| 2026-03-27 | 8-K | form8-k.htm |
| 2026-03-24 | 8-K | form8-k.htm |
| 2026-03-10 | 8-K | form8-k.htm |
| 2026-03-02 | 8-K | form8-k.htm |
| 2026-03-02 | 10-K | form10-k.htm |
| 2026-02-02 | 8-K | form8-k.htm |
| 2025-11-18 | 8-K | form8-k.htm |
| Mr. Michael D. Biega | Vice President of Investor Relations & Communications |
| Mr. Patrick W. Sullivan | Chief Commercial Officer |
| Mr. Randall E. Pollard | Chief Accounting Officer |
| Ms. Kim Barratt | Chief Talent Officer |